Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee's enthusiasm for sunitinib was tempered by complexities resulting from the pivotal trial's early termination, and the panel urged that everolimus only be used for patients with aggressive disease.
You may also be interested in...
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.
Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease
FDA approval of Novartis' everolimus for progressive pancreatic neuroendocrine tumors is in line with the Oncologic Drugs Advisory Committee's recommendations that the drug be reserved for those patients with more serious disease.